Gynaecological Cancer Research Needs Urgent Investment
On May 13, 2026, the Australian Federal Government announced a significant increase in its Medical Research Future Fund (MRFF), raising it from $650 million to $1 billion annually by 2030-31. This announcement, made in the Federal Budget, is a welcome advancement for the medical research sector in Australia.
The Australia New Zealand Gynaecological Oncology Group (ANZGOG), Ovarian Cancer Australia (OCA), and Ovarian Cancer Research Foundation (OCRF) have expressed their approval of this increase. Still, they emphasise the urgent requirement for focused investment in gynaecological cancer research to address critical gaps in the sector.
In Australia, 19 women are diagnosed with gynaecological cancers daily, including ovarian, uterine, cervical, vulvar, and vaginal cancers. Alarmingly, diagnoses are projected to rise by 21% over the next decade. More than 55% of these cases are rare, with limited treatment options and no routine early detection tests, aside from cervical cancer.
Tragically, over six women die from gynaecological cancers each day, totaling more than 2,500 deaths annually. Despite advances in other areas, survival rates for these cancers have seen little improvement over the decades. Women in rural, regional, and remote areas, as well as those from lower socioeconomic and diverse backgrounds, face significant disparities in access to diagnosis, treatment, and clinical trials.
Call for Dedicated Gynaecological Cancer Funding
ANZGOG, OCA, and OCRF are advocating for the Gynaecological Cancer Transformation Initiative (GCTI), a nationally coordinated, evidence-based effort. This initiative focuses on enhancing prevention, early diagnosis, treatment, clinical trials, survivorship, and supportive care for women with gynaecological cancers.
Alison Evans, CEO of ANZGOG, emphasised the importance of including gynaecological cancers in national research priorities. She stated, "We will continue to advocate to ensure gynaecological cancers are clearly included within this opportunity, so that women are not overlooked."
Supportive care remains a critical yet often neglected aspect of cancer treatment, as many women face severe physical, emotional, and financial challenges during their diagnosis and treatment. The GCTI aims to address these issues through a coordinated approach that aligns with the Australian Cancer Plan, providing a comprehensive strategy to improve patient outcomes.
Last updated: 13 May 2026, 10:50 pm
